June 2022

Progress in therapeutics and diagnosis over the past decade has dramatically shifted the treatment landscape for this genetic epilepsy and rapidly advanced patient care.

Achieving greater diversity in study populations is a focus of increasing scrutiny, priority, and funding in all medical research, including studies enrolling individuals on the continuum of prodromal Alzheimer disease, mild cognitive impairment, and Alzheimer disease.

The agent will be evaluated in 2 pivotal trials of 225 patients requiring varying levels of assistance with daily living activities.

Although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.

Given the importance of mitochondrial and endoplasmic reticulum function in ALS, the disruption of intracellular mitochondria-endoplasmic reticulum contacts presents yet another avenue for neuronal degeneration—perhaps the primary point of underlying dysfunction.

The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.

The oral version offers the same efficacy as the previously approved intravenous treatment.

The early-stage clinical trial will include 40 healthy volunteers to evaluate the safety and immune response of an investigational EBV gp350-Ferritin nanoparticle vaccine with a saponin-based Matrix-M adjuvant.

The approval is supported by phase 3 data which showed statistically significant differences on MG-ADL and QMG scores relative to placebo following 26 weeks of treatment.

After readjusting baseline to month 12, more patients with relapsing multiple sclerosis on continuous ozanimod achieved NEDA-3 and NEDA-4 status than those on interferon ß-1a.

Following the switch to ubrogepant, more than half of patients with migraine had reduced use of triptans and more than one-third of patients had reduced use of anti-inflammatory drugs.

On fluorodeoxyglucose PET, pepinemab slowed or reversed decline in metabolic activity in all 26 brain regions observed, with significant benefit found in 15 regions.

Interim data from the phase 2 RESCUE-ALS trial open-label extension suggest that Clene Nanomedicine’s investigational agent, CNM-AU8, offered benefits to patients with ALS in terms of survival, in addition to prior results suggestive of slowed progression.

The director of Cleveland Clinic’s Epilepsy Center discussed the new Cleveland Clinic Brain Study, which will evaluate predisease fingerprints from patients who go on to develop neurological disorders.